Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 4Breast 2Other 1

Conditions

Breast Neoplasms 2Sexual Dysfunctions, Psychological 1Breast Neoplasms, Male 1

Interventions

Letrozole 34Fulvestrant 31Specimen Handling 29ribociclib 22pembrolizumab 22Paclitaxel 21Magnetic Resonance Spectroscopy 20palbociclib 19Trastuzumab 19Anastrozole 19Carboplatin 18Capecitabine 18exemestane 17abemaciclib 16Biopsy 16Tamoxifen 15pertuzumab 14trastuzumab deruxtecan 12Cyclophosphamide 10Taxes 9Radiotherapy 8Goserelin 8Docetaxel 8giredestrant 7Standard of Care 7130-nm albumin-bound paclitaxel 7inavolisib 6eribulin 6elacestrant 6atezolizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leuprolide × Breast × 30 days × Clear all
NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡